These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 32503989)
1. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Wang D; Liu X; Wei M; Qian C; Song S; Chen J; Wang Z; Xu Q; Yang Y; He M; Chi X; Huang S; Li T; Kong Z; Zheng Q; Yu H; Wang Y; Zhao Q; Zhang J; Xia N; Gu Y; Li S Nat Commun; 2020 Jun; 11(1):2841. PubMed ID: 32503989 [TBL] [Abstract][Full Text] [Related]
2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
3. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro. Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257 [TBL] [Abstract][Full Text] [Related]
4. Developments in L2-based human papillomavirus (HPV) vaccines. Schellenbacher C; Roden RBS; Kirnbauer R Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616 [TBL] [Abstract][Full Text] [Related]
5. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. Tumban E; Peabody J; Peabody DS; Chackerian B PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes. Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963 [TBL] [Abstract][Full Text] [Related]
7. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9. Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477 [TBL] [Abstract][Full Text] [Related]
8. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses. Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932 [TBL] [Abstract][Full Text] [Related]
9. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766 [TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic. Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614 [TBL] [Abstract][Full Text] [Related]
11. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055 [TBL] [Abstract][Full Text] [Related]
12. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197 [TBL] [Abstract][Full Text] [Related]
13. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity. Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196 [TBL] [Abstract][Full Text] [Related]
14. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935 [TBL] [Abstract][Full Text] [Related]
15. Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines. Zhang T; Chen X; Liao G; Hu M; Xu J; Xu X J Med Virol; 2020 Dec; 92(12):3750-3758. PubMed ID: 31994744 [TBL] [Abstract][Full Text] [Related]
16. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity. Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274 [TBL] [Abstract][Full Text] [Related]
17. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen. Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071 [TBL] [Abstract][Full Text] [Related]
18. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types. Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176 [TBL] [Abstract][Full Text] [Related]
19. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Murata Y; Lightfoote PM; Rose RC; Walsh EE Virol J; 2009 Jun; 6():81. PubMed ID: 19538743 [TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of a Nonadjuvant Human Papillomavirus Type 6 Virus-like Particle Vaccine in Recurrent Respiratory Papillomatosis. Zhang CQ; Yi S; Liu XJ; Nan BY; Huang SY; Chen BB J Voice; 2019 May; 33(3):363-369. PubMed ID: 30224308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]